Simmons Comprehensive Cancer Center Distinguished Lecture Series

“From Metabolic Stress Signaling to Therapeutic Approaches in Cancer and Neurodegeneration”

Michael Rapé, Ph.D.

Investigator, HHMI

Professor and Head, Division of Molecular Therapeutics

MCB, University of California, Berkeley

Hosted by: Matthew Sieber, Ph.D.

Monday, September 21st | Noon

NB5.124 Seminar Room (In-person Preferred)

Hybrid:

ZOOM Meeting

Meeting ID: 986 1181 6387

Passcode: 977960

About Dr. Michael Rapé:

Michael Rapé is a Professor and Founding Head of the new Division of Molecular Therapeutics in the Department of Molecular Cell Biology. He is also an Investigator with HHMI and the Dr. K. Peter Hirth Chair of Cancer Biology.  The Michael Rapé Lab is implementing a combination of genetic screens, structural biology, biochemistry, and high-throughput chemical screening to discover stress response pathways that safeguard human development. They are also interested in developing first-in-class therapeutic modalities for the treatment of cancer and neurodegenerative disease. Rapé is co-founder of four biotech companies, including Nurix Therapeutics as the first company focused on targeted protein degradation. Nurix is now a publicly traded and clinical-stage company. Rapé is also an iPartner with The Column Group venture firm.
 Meet the P.I.: https://vcresearch.berkeley.edu/faculty/michael-rape